Have a feature idea you'd love to see implemented?
Let us know!
SCPH scPharmaceuticals Inc
Price (delayed)
$3.46
Market cap
$173.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.9
Enterprise value
$160.98M
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships,
Highlights
The revenue rose by 26% since the previous quarter
scPharmaceuticals's gross profit has increased by 23% QoQ
The company's quick ratio has surged by 91% QoQ but it fell by 23% YoY
SCPH's debt has soared by 99% YoY and by 92% QoQ
scPharmaceuticals's net income has shrunk by 59% YoY and by 32% QoQ
Key stats
What are the main financial stats of SCPH
Market
Valuations
Earnings
Shares outstanding
50.04M
Market cap
$173.14M
Enterprise value
$160.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.64
Price to sales (P/S)
5.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.32
Revenue
$30.28M
EBIT
-$71.94M
EBITDA
-$71.71M
Free cash flow
-$70.56M
Per share
Balance sheet
Liquidity
EPS
-$1.9
Free cash flow per share
-$1.52
Book value per share
$0.61
Revenue per share
$0.65
TBVPS
$2.69
Total assets
$125.07M
Total liabilities
$94.36M
Debt
$79.33M
Equity
$30.71M
Working capital
$108.07M
Debt to equity
2.58
Current ratio
8.08
Quick ratio
6.6
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-236.8%
Gross margin
69.7%
Net margin
-264.6%
Operating margin
-210.4%
Return on assets
-88.2%
Return on equity
-315%
Return on invested capital
-104.1%
Return on capital employed
-65.5%
Return on sales
-237.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCPH stock price
How has the scPharmaceuticals stock price performed over time
Intraday
2.98%
1 week
2.98%
1 month
-21.72%
1 year
-38.54%
YTD
-44.82%
QTD
-24.12%
Financial performance
How have scPharmaceuticals's revenue and profit performed over time
Revenue
$30.28M
Gross profit
$21.11M
Operating income
-$63.69M
Net income
-$80.12M
Gross margin
69.7%
Net margin
-264.6%
scPharmaceuticals's operating margin has soared by 68% YoY and by 16% from the previous quarter
SCPH's net margin has soared by 61% YoY but it is down by 4.9% QoQ
scPharmaceuticals's net income has shrunk by 59% YoY and by 32% QoQ
scPharmaceuticals's operating income has decreased by 28% YoY and by 5% QoQ
Growth
What is scPharmaceuticals's growth rate over time
Valuation
What is scPharmaceuticals stock price valuation
P/E
N/A
P/B
5.64
P/S
5.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.32
The company's EPS fell by 40% YoY and by 22% QoQ
The price to book (P/B) is 41% less than the last 4 quarters average of 9.5 but 28% more than the 5-year quarterly average of 4.4
The equity has contracted by 38% YoY
SCPH's price to sales (P/S) is 50% lower than its last 4 quarters average of 10.7
The revenue rose by 26% since the previous quarter
Efficiency
How efficient is scPharmaceuticals business performance
scPharmaceuticals's return on invested capital has shrunk by 109% YoY and by 39% QoQ
The return on assets has dropped by 107% year-on-year and by 25% since the previous quarter
The company's return on sales has surged by 58% YoY but it fell by 9% QoQ
SCPH's ROE has dropped by 56% since the previous quarter
Dividends
What is SCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCPH.
Financial health
How did scPharmaceuticals financials performed over time
The company's total assets is 33% higher than its total liabilities
The company's total assets has surged by 91% QoQ and by 18% YoY
The company's quick ratio has surged by 91% QoQ but it fell by 23% YoY
SCPH's debt is 158% higher than its equity
SCPH's debt has soared by 99% YoY and by 92% QoQ
SCPH's debt to equity is down by 42% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.